For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Blog
This week in health care policy: October 16–23, 2026
Medical innovation FDA approves several innovative treatments. Last week, the FDA granted accelerated approval to GSK’s Jemperli for certain untreated…
Blog
This week in health care policy: October 8–15, 2026
Innovation watch Merck expects faster production of its personalized cancer vaccine. CEO Rob Davis told CNBC the six-week turnaround for…
Search Posts
Blog
Can AI thrive in health care’s HIPAA-shaped box?
Innovation continues to transform health care, enabling us to live longer and healthier lives. And now artificial intelligence (AI) is poised to supercharge…
The Wall Street Journal
The FTC Goes Evidence-Free
Through three years of Lina Khan’s leadership, the Federal Trade Commission has suffered an unprecedented streak of high-profile court defeats. That’s because the agency regularly…
Blog
This week in ridiculous regulations: Blood donors and paper marketing
Donald Trump survived an assassination attempt. The Republicans held their convention in Milwaukee. Sen. Robert Menendez (D-NJ) was convicted on bribery charges and resigned,…
Blog
Missing the economists in FTC’s latest PBM study
The Federal Trade Commission (FTC) released its not-so-objectively titled interim report on Pharmacy Benefit Managers (PBMs): Pharmacy Benefit Managers: The Powerful Middlemen Inflating…
News Release
New FTC study on drug costs fails to conduct empirical analysis of market conditions
The Federal Trade Commission (FTC) release a new study today claiming Pharmacy Benefit Managers (PBMs) are responsible for higher drug costs. FTC Commissioner Melissa…
Penn Live
Harrisburg is taking a wrong approach to drug pricing | PennLive letters
CEI’s Joel Zinberg was cited in a Penn Live article on Pharmacy Benefit Managers: Joel Zinberg from the Competitive Enterprise Institute (CEI) explains,…